Navigation Links
SureClinical Completes FDA 21 CFR Part 11 Compliance Audit of SureTrial® eTMF Cloud Edition
Date:8/1/2013

Rancho Cordova, CA (PRWEB) August 01, 2013

SureClinical, a provider of cloud-based content management application software and services for health sciences, announced today that it has successfully completed an FDA 21 CFR Part 11 compliance audit of its SureTrial® eTMF clinical trials content management application. More information is available at http://www.SureTrial.com.

Conducted through a leading independent GxP process auditing organization, SureTrial’s successful audit will help sponsors, clinical research organizations, academic research organizations and investigator sites running clinical trials comply with FDA rules and regulations related to electronic records and electronic signatures used in Electronic Trial Master File, or eTMF implementations.

“SureTrial eTMF is the first eTMF cloud software solution that completely addresses FDA 21 CFR Part 11 regulations and that has successfully completed an independent audit and validation,” said Zack Schmidt, President and CEO of SureClinical. “With the independent audit and validation of SureTrial eTMF, life sciences organizations can accelerate their compliance and validation initiatives for faster application deployment, insuring higher levels of GxP process management with eTMF documents and medical images.”

The FDA 21 CFR Part 11 compliance audit was performed by a leading independent GxP process organization that provides training to industry and US FDA regulatory agency personnel on 21 CFR Part 11 regulated computerized systems. The audit covered requirements for electronic records and electronic signatures under 21 CFR Part 11.

About SureClinical

SureClinical is a provider of cloud-based content management application software for health sciences. Headquartered in the Northern California, SureClinical’s founders have proven expertise in delivering market leading enterprise applications in the health sciences and enterprise mobile computing areas. To find out more, visit http://www.SureClinical.com.

###

Trademarks
SureClinical, SureTrial®, SureTrial® eTMF are trademarks of SureClinical.

Copyright © 2013 SureClinical. All rights reserved. SureClinical, SureTrial eTMF and the SureTrial logo are trademarks of SureClinical. Other names used herein may be trademarks of their respective owners.

http://www.SureClinical.com
http://www.SureTrial.com

Read the full story at http://www.prweb.com/releases/2013/8/prweb10982140.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Biocartis Completes EUR 71 Million (USD 100 Million) Series C Fund Raising
2. InnoPharma Completes $15 Million Series A Financing
3. Aratana Therapeutics Completes $15 Million Series B Financing
4. CeNeRx BioPharma Completes $4.85 Million Financing
5. PDL BioPharma Completes Regular Quarterly Dividend Payment
6. MiMedx Group Completes $5,000,000 Private Placement
7. goBalto Completes a Successful FDA 21 CFR Part 11 Compliance Audit
8. Auxogyn Completes $20 Million In Series A Funding
9. CitiusTech Completes Another Milestone Year: Revenues Grow by 59% in 2011
10. GeneLink Biosciences Completes Sale of GeneWize Life Sciences
11. Ikaria® Completes Patient Enrollment in Pivotal Phase III Trial for Bronchopulmonary Dysplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... -- Atrius Health and IBM (NYSE: IBM ) ... develop a cloud based service designed to improve ... of the multiple influences on an individual,s health, ... designed to support shared decision making between physicians ... healthcare organization with 875 physicians caring for 675,000 ...
(Date:2/18/2017)... Research and Markets has announced the addition of the ... ... provides separate comprehensive analytics for the US, Japan ... estimates and forecasts are provided for the period 2015 through 2022. ... data and analytics are derived from primary and secondary research. This ...
(Date:2/17/2017)... MILPITAS, Calif. , Feb. 17, 2017 /PRNewswire/ ... posters detailing data on its oral peptide drug ... Congress of the European Crohn,s and Colitis ... in Barcelona, Spain from ... The posters detail preclinical data on Protagonist drug ...
(Date:2/16/2017)... , Feb. 16, 2017  MDNA Life ... the development of liquid biopsy tests based on ... into an exclusive license agreement with its first ... proprietary liquid biopsy test for prostate cancer, the ... Korea . This is the first overseas ...
Breaking Biology Technology:
(Date:1/24/2017)... 2017 Biopharm Reports has carried out ... of nuclear magnetic resonance spectroscopy (NMR). This involved ... current practices, developments, trends and end-user plans over ... and opportunities. These areas include growth in the ... and innovation requirements, hyphenated NMR techniques, main suppliers ...
(Date:1/19/2017)... PUNE, India , January 19, 2017 ... Sensor Market, Opportunities and Forecast, 2014 - 2022," the global biometric sensor ... of 9.6% from 2016 to 2022. In 2015, Asia-Pacific ... for both public and private sectors. Continue Reading ... ...
(Date:1/13/2017)... 2017 Sandata Technologies, LLC, a leading ... industry, including Electronic Visit Verification™ (EVV™), announced today ... as Senior Vice President of Product Management. ... homecare experience to Sandata, where he will be ... align Sandata,s suite of solutions with the needs ...
Breaking Biology News(10 mins):